Targeting Oxidative Stress in Chronic Beryllium Disease

Summary

The purpose of this study is to understand if a drug called mesalamine helps to control inflammation associated with chronic beryllium disease (CBD). We hypothesize that in CBD subjects treated with prednisone, mesalamine treatment will enhance the immunosuppressive effects of prednisone, and thus reduce the immune response to beryllium.

Timeline

Start

2010-03

Primary completion

2015-03

Completion

2015-03

Drugs

Indications